NASDAQ · SRZN
Surrozen, Inc.
$29.04-$0.42 (-1.43%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.24% below the high.
Loading market information…
OTC · HEPA · USD
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Hepion Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Hepion Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$200.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hepion Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 08:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 |
|---|
| Nov 14, 2024 |
| -$36.00+62.11% vs estimate |
| $0.00 |
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.04-$0.42 (-1.43%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.24% below the high.
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
$6.63+$0.13 (+2.0%)
Envoy Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.5% below the high.
$1.60-$0.22 (-12.09%)
SCWorx Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.65% below the high.
$1.43-$0.03 (-2.05%)
Enveric Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.21% below the high.
$0.98-$0.16 (-14.05%)
NewGenIvf Group Limited’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
$0.11$0.00 (0.0%)
Longevity Health Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.41% below the high.
$0.00$0.00 (0.0%)
Petros Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.67% below the high.
